brand logo

Am Fam Physician. 2022;106(5):575-577

Author disclosure: No relevant financial relationships.

Binx IO is a cartridge-based test with a Clinical Laboratory Improvement Amendment (CLIA) waiver that detects Chlamydia trachomatis and Neisseria gonorrhoeae infections in patients with or without symptoms.1 The molecular assay is performed by clinicians using vaginal swabs or male urine specimens. Results are available in 30 minutes, allowing for testing and treatment in a single visit.1

Binx IO point-of-care testScreening and diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae infectionsSymptomatic and asymptomatic adults$70.20
Already a member/subscriber?  Log In


From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available

Issue Access

  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

This series is coordinated by Natasha Pyzocha, DO, contributing editor.

A collection of Diagnostic Tests published in AFP is available at

Continue Reading

More in AFP

More in PubMed

Copyright © 2022 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.